## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.07 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($193.90)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Dow's 132-point rally led by gains for Johnson & Johnson, Procter & Gamble stocks**
- Source: MSN | 20251209T152020 | Bullish | Relevance: 99%
- The Dow Jones Industrial Average rose by 132 points, driven primarily by strong performances from Johnson & Johnson and Procter & Gamble stocks. This rally indicates positive movement within the industrial average, influenced by these key companies.

**2. Health changes everything: Europe’s smart investment**
- Source: Economist Impact | 20251209T090851 | Bullish | Relevance: 99%
- Europe faces demographic challenges including an aging population and rising chronic disease, which threaten economic growth. The article argues that treating healthcare as an investment rather than a cost can drive productivity, competitiveness, and prosperity, citing economic benefits that far outweigh the initial investment. It highlights how past austerity measures weakened health systems and calls for political decision-makers to prioritize long-term health outcomes and innovation.

**3. J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma**
- Source: BioPharma Dive | 20251209T130817 | Bullish | Relevance: 99%
-  New data from Johnson & Johnson's MajesTEC-3 trial suggest that a Tecvayli-based combination therapy could offer a curative potential when used early in the treatment of multiple myeloma. The combination of Tecvayli with Darzalex significantly reduced the risk of disease progression or death by 83% and led to an 82% complete response rate, compared to standard treatments. This positive outcome points to a future where bispecific antibodies like Tecvayli could be moved to earlier lines of care, offering a more accessible alternative to CAR-T therapies, though vigilance regarding infection risks remains crucial.

**4. Paxton Secures Major Win Against Johnson & Johnson and Kenvue**
- Source: Texas Border Business | 20251208T191740 | Neutral | Relevance: 98%
-  Attorney General Ken Paxton secured a legal victory against Johnson & Johnson and Kenvue, obtaining a Temporary Restraining Order for their operations in Texas without required registrations. The companies failed to comply with the Texas Business Organizations Code, which mandates foreign entities to register before conducting business in the state. Paxton emphasizes his commitment to holding powerful corporations accountable and protecting Texans' well-being over corporate greed.

**5. Key facts: Johnson & Johnson Raises Dividend; Reports Positive Study Results**
- Source: TradingView | 20251209T200755 | Bullish | Relevance: 98%
-  Johnson & Johnson (JNJ) has increased its dividend for 63 consecutive years, offering a 2.58% yield with an annual payout of $5.20. The company also announced positive Phase 3 study results for TECVAYLI and DARZALEX FASPRO in treating relapsed multiple myeloma patients.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Guggenheim | $227 | $206 | +10% |
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Guggenheim | main | Buy |
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.26M) |
| Sells | 7 ($4.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.3% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $4.1M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 17.4x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($4.1M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $481.8B |
| Beta | 0.35 |
| 52W Range | $140.68 - $207.81 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.4 |
| Current P/E | 18.4 |
| YoY Growth | 6.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.4% to -3.0% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.91), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.97% (CS: 36) | Weak |
| RSI_14 | 52.4 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.172x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $199.96
- **Stop Loss:** $193.90 (3.0% risk)
- **Target:** $212.08 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $9,798.04
- **Portfolio %:** 9.80%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*